OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Yu on the Significance of the PROTECT Study in Prostate Cancer

May 9th 2017

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses the significance of the PROTECT study results in prostate cancer.

Dr. Burstein on Adjuvant Endocrine Therapy for ER+ Breast Cancer

May 9th 2017

Harold J. Burstein, MD, PhD, senior physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses adjuvant endocrine therapy for postmenopausal women with ER-positive breast cancer.

Dr. Meinhardt on the Impact of the RESORCE Study in HCC

May 9th 2017

Gerold Meinhardt, MD, global clinical leader at Bayer Pharmaceuticals, discusses the impact of the RESORCE trial in hepatocellular carcinoma.

Dr. Jain Discusses Treatment of Richter's Transformation in CLL

May 8th 2017

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with chronic lymphocytic leukemia who have developed Richter’s transformation.

Dr. Turaga Discusses Current Surgical Setting of Sarcoma

May 8th 2017

Kiran Turaga, MD, MPH, surgical oncologist, University of Chicago Cancer Center, discusses the current surgical setting of sarcoma.

Dr. Carey on De-Escalating Treatments for Triple-Negative Breast Cancer

May 8th 2017

Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses de-escalating treatments for patients with triple-negative breast cancer (TNBC).

Dr. Philip on the Importance of Developing New Drugs for Pancreatic Cancer

May 8th 2017

Philip A. Philip, MD, PhD, FRCP, professor of Medicine, Wayne State University School of Medicine, clinical professor of Oncology at Barbara Ann Karmanos Cancer Institute, discusses the importance of developing new drugs for patients with pancreatic cancer.

The Long-Term Potential of Olaratumab in Soft Tissue Sarcoma

May 8th 2017

Symantha Melemed, global product team lead, Oncology Business Unit, Eli Lilly & Company, discusses the impact of the FDA approval of olaratumab (Lartruvo) in patients with soft tissue sarcoma

Dr. Niesvizky on Exciting Changes in the Multiple Myeloma Landscape

May 8th 2017

Ruben Niesvizky, MD, professor of medicine, Joan and Sanford I. Weill Department of Medicine , Weill Cornell Medical College/NewYork-Presbyterian Hospital, discusses some of the exciting changes that have occurred in the field of multiple myeloma.

Dr. Febbo on the Impact of Oncotype DX Genetic Prostate Score

May 6th 2017

Phil Febbo, MD, chief medical officer, Genomic Health, discusses the impact the Oncotype DX Genetic Prostate Score (GPS) has on patients with clinically low-risk prostate cancer.

Dr. Abou-Alfa on the Role of Immunotherapy in HCC

May 6th 2017

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of immunotherapy for patients with hepatocellular carcinoma (HCC).

Dr. Martin on Patient Preferences With MCL Treatment

May 5th 2017

Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian, discusses preferences patients have for their treatment of mantle cell lymphoma (MCL).

Dr. Leonard on Emergence of CAR T-cell Therapy in Hematologic Cancers

May 5th 2017

John P. Leonard, MD, associate dean of Clinical Research, interim chair of the Department of Medicine, Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the emergence and potential of chimeric antigen receptor (CAR) T-cell therapy across hematologic malignancies.

Dr. Hammers on Combination of Vaccines and Immune Checkpoint Inhibitors in RCC

May 5th 2017

Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the combination of vaccines and immune checkpoint inhibitors in the treatment of patients with renal cell carcinoma.

Dr. Wierda on the Need for Continuous Treatment for CLL

May 5th 2017

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses the need for continuous treatments for patients with chronic lymphocytic leukemia (CLL).

Dr. Kirsh on Advancements in Diagnosing Prostate Cancer

May 5th 2017

Gary Kirsh, MD, president of The Urology Group and the Large Urology Group Practice Association (LUGPA), discusses advancements in diagnosing patients with prostate cancer.

Rationale for Targeting Galectin-1 in Head and Neck Cancer

May 4th 2017

Dhanya K. Nambiar, PhD, Stanford University, explains the rationale behind targeting Galectin-1 (Gal-1) in head and neck cancer.

Dr. Strosberg on Challenges in the Treatment of Neuroendocrine Tumors

May 4th 2017

Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the challenges associated with treating neuroendocrine tumors (NETs).

Dr. Muggia on Targeted Therapies for Ovarian Cancer

May 4th 2017

Franco M. Muggia, MD, PhD, professor, Department of Medicine, NYU Langone Medical Center, discusses targeted therapies for patients with ovarian cancer.

Dr. Apolo on Avelumab for Metastatic Urothelial Carcinoma

May 4th 2017

Andrea B. Apolo, MD, medical oncologist at the National Cancer Institute, chief of the bladder cancer section of the Genitourinary Malignancies Branch, discusses avelumab (Bavencio) in patients with metastatic urothelial carcinoma from the phase Ib JAVELIN solid tumor trial.